LEXXHIGH SIGNALFINANCIAL10-K

LEXX's R&D expenses surged 249% to $8.2M while stockholders' equity plummeted 63% and total assets declined 53%, indicating significant cash burn despite maintaining technology development focus.

The massive increase in R&D spending alongside the sharp decline in assets and equity suggests the company is aggressively investing in development while rapidly consuming its capital base. The company appears to be in a critical phase where it must either secure additional funding or demonstrate meaningful progress from its increased R&D investment to avoid potential liquidity issues.

Comparing 2025-11-28 vs 2024-11-26View on EDGAR →
FINANCIAL ANALYSIS

LEXX shows a concerning pattern of dramatically increased spending with R&D expenses jumping 249% while the company's financial foundation eroded significantly - stockholders' equity fell 63%, total assets dropped 53%, and operating cash flow worsened 111% to -$10.5M. Despite gross profit improving 53%, the company's aggressive R&D investment strategy has substantially weakened its balance sheet and cash position. This financial profile suggests LEXX is betting heavily on R&D breakthroughs while operating under increasing capital constraints that may require external funding or strategic partnerships to sustain operations.

FINANCIAL STATEMENT CHANGES
R&D Expense
P&L
+249%
$2.4M$8.2M

R&D investment increased 249% — signals commitment to future product development, though near-term margin impact.

Interest Expense
P&L
+167.3%
$2K$6K

Interest expense surged 167.3% — significant debt increase or rising rates materially impacting earnings.

Accounts Receivable
Balance Sheet
+138.5%
$154K$368K

Receivables surged 138.5% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Operating Cash Flow
Cash Flow
-110.7%
-$5.0M-$10.5M

Operating cash flow fell 110.7% — earnings quality concerns; investigate working capital changes and non-cash items.

Operating Income
P&L
-106.5%
-$5.8M-$11.9M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Net Income
P&L
-105.4%
-$5.8M-$11.9M

Net income declined 105.4% — review whether driven by operations, interest costs, or non-recurring items.

Stockholders Equity
Balance Sheet
-62.8%
$8.0M$3.0M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Current Assets
Balance Sheet
-56.1%
$7.9M$3.5M

Current assets declined 56.1% — monitor working capital adequacy and short-term liquidity.

Gross Profit
P&L
+53.1%
$459K$703K

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Total Assets
Balance Sheet
-52.9%
$8.9M$4.2M

Total assets contracted 52.9% — asset sales, write-downs, or balance sheet optimization underway.

LANGUAGE CHANGES
NEW — 2025-11-28
PRIOR — 2024-11-26
ADDED
During the three months ended August 31, 2025, no director or officer of the Company adopted or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement, as each term is defined in Item 408(a) of Regulation S-K.
is a biotechnology company dedicated to the enhancement of the bioavailability of a diverse and broad range of active pharmaceutical ingredients ( APIs ) using our patented DehydraTECH TM drug delivery technology.
DehydraTECH can be used with a wide range of active molecules including glucagon-like peptide-1 drugs ( GLP-1 ) and glucose-dependent insulinotropic polypeptide drugs ( GIP ), vitamins, pain medications, hormones, antivirals, nicotine and its analogs, and cannabinoids.
DehydraTECH can be implemented in a multitude of ingestible product formats including oral suspensions, tablets, capsules, foods, beverages, and oral pouches.
While the Company s primary focus is on pharmaceutical drug products, this technology extends across many product categories including nutraceuticals, foods and beverages.
+7 more — sign up free →
REMOVED
is a biotechnology company dedicated to the enhancement of the bioavailability of a broad range of active pharmaceutical ingredients ( APIs ) using our patented DehydraTECH TM drug delivery-enabling platform technology.
DehydraTECH can be used with a wide range of active molecules including glucagon-like peptide-1 drugs ( GLP-1 ) and glucose -dependent insulinotropic polypeptide drugs ( GIP ), vitamins, pain medications, hormones, phosphodiesterase type 5 ( PDE5 ) inhibitors, antivirals, nicotine and its analogs, and cannabinoids.
DehydraTECH can be implemented in a multitude of ingestible or topically administered product formats including oral suspensions, tablets, capsules, foods, beverages, creams, lotions, and skin patches.
While the Company s primary focus is on pharmaceutical drug products, this technology extends across many product categories including foods, beverages, cosmetics and nutraceuticals.
Our current patent portfolio includes patent family applications or grants pertaining to Lexaria s compositions, methods of use in improving API bioavailability and palatability and methods of treatment for a range of therapeutic indications, orally or topically, for a wide variety of APIs encompassing cannabinoids; fat soluble vitamins; NSAID pain medications; and nicotine and its analogs.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →